Abstract
Current vaccine research is now heavily focused on improving the efficacy and potency of sub-unit peptide vaccines. Many successful vaccines developed in past decades have been able to sufficiently prime proper immune responses without the use of any specific adjuvant immune mediators. Due to the intrinsic nature of more immune-evading pathogens and neoplasms, novel “tricks” are needed to elucidate a proper and protective immune response. It is important to note that without cytokines, proper execution of the immune response would be completely inhibited. They are responsible for the recruitment and chemo-tactic movement of most innate cellular effectors such as polymorphonucleocytes (PMN), macrophages, and dendritic cells. Most importantly, the entire Th1/Th2 balance is completely dependent on the unique nature and signature of differential cytokine production. These expression signatures are crucially needed to tip the scale either way, depending on which immune reaction is appropriate. This review will specifically explain the use of Th1 inducing cytokines as an adjuvant in current vaccine development. This rapidly developing field aims to produce more powerful and effective Th1 responses in the hopes of improving the treatment of cancer, intracellular infectious agents, and autoimmune diseases.
Keywords: Vaccines, sub-unit vaccines, peptides, cytokines, adjuvants, Th1/Th2 responses
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Volume: 8 Issue: 4
Author(s): Sebastian Di Cesare, Daniel Abourbih, Rubens N. Belfort, Luca A. Petruccelli and Miguel N. Burnier Jr.
Affiliation:
Keywords: Vaccines, sub-unit vaccines, peptides, cytokines, adjuvants, Th1/Th2 responses
Abstract: Current vaccine research is now heavily focused on improving the efficacy and potency of sub-unit peptide vaccines. Many successful vaccines developed in past decades have been able to sufficiently prime proper immune responses without the use of any specific adjuvant immune mediators. Due to the intrinsic nature of more immune-evading pathogens and neoplasms, novel “tricks” are needed to elucidate a proper and protective immune response. It is important to note that without cytokines, proper execution of the immune response would be completely inhibited. They are responsible for the recruitment and chemo-tactic movement of most innate cellular effectors such as polymorphonucleocytes (PMN), macrophages, and dendritic cells. Most importantly, the entire Th1/Th2 balance is completely dependent on the unique nature and signature of differential cytokine production. These expression signatures are crucially needed to tip the scale either way, depending on which immune reaction is appropriate. This review will specifically explain the use of Th1 inducing cytokines as an adjuvant in current vaccine development. This rapidly developing field aims to produce more powerful and effective Th1 responses in the hopes of improving the treatment of cancer, intracellular infectious agents, and autoimmune diseases.
Export Options
About this article
Cite this article as:
Di Cesare Sebastian, Abourbih Daniel, Belfort N. Rubens, Petruccelli A. Luca and Burnier Jr. N. Miguel, Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (4) . https://dx.doi.org/10.2174/187152309789839046
DOI https://dx.doi.org/10.2174/187152309789839046 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Chlorogenic Acid Suppresses a Cell Adhesion Molecule in Experimental Autoimmune Myocarditis in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Vitamin D : Autoimmunity and Gender
Current Medicinal Chemistry Synthetic Peptides in the Diagnosis of Neurological Diseases
Current Protein & Peptide Science Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Development and Chemistry of Histamine H4 Receptor Ligands as Potential Modulators of Inflammatory and Allergic Responses
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews Antibody-Mediated Endothelial Cell Damage Via Nitric Oxide
Current Pharmaceutical Design Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Immunology of VIP: A Review and Therapeutical Perspectives
Current Pharmaceutical Design Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Inhibitors Targeting the LFA-1/ICAM-1 Cell-Adhesion Interaction: Design and Mechanism of Action
Current Pharmaceutical Design The Emergence of Multiplexed Technologies as Diagnostic Platforms in Systemic Autoimmune Diseases
Current Medicinal Chemistry Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design Selective Binding BAFF/APRIL by the In and Outside Conservative Region of BCMA
Protein & Peptide Letters